Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

Inclusion Criteria: * Aged over 19 years * Signed informed consent form * At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyceride ≤ 400mg/dL Exclusion Criteria: * At visit 1, BMI ≥ 30kg/㎡ * Has a history of myopathy or rhabdomyolysis cased by statin treatment, hereditary myopathy or family history and hypersensitivity to statin(HMG-CoA reductase inhibitor) and component of ezetimibe * Has a Severe renal disorder(Ccr \<30mL/min) or nephrotic syndrome * Creatine Kinase \> 5 x upper limit of normal * ALT or AST \> 3 x upper limit of normal * Has a activity/chronic hepatic disease or HIV-positive * Has a endocrine or metabolic diseases known to affect the serum phospholipid or protein * Uncontrolled diabetes mellitus(HbA1c ≥9%) * Hypothyroidism (TSH \> 1.5 x upper limit of normal rate at the screening ) * Uncontrolled hypertension (SBP ≥180mmHg or DBP ≥110mmHg) * Has a acute arteriopathy(history of unstable angina, cardiac infarction, transient ischemic stroke, cerebrovascular disease, coronary artery bypass, coronary intervention within 12 weeks prior to screening) * Severe heart failure (NYHA Class III or IV) * Has a drug absorption disorder by gastrointestinal surgery or gastrointestinal disorder * History of malignant tumor including myelogenous and lymphoma within 5 years (Participation is possible, if the tumor has not recurred for more than 5 years) * Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption * Female subjects of childbearing potential who disagree with the contraceptive methods(surgical sterilization, intrauterine device or condoms) * Pregnant or breast-feeding * Patients who have a drug or alcohol abuse or are being treated for psychological disorder * Patients who were treated with other investigational drug within 12 weeks prior to screening * Other patients who are inappropriate to participate in the study considered by the investigator or other study staffs